SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics ($MLTX) is trending due to a significant stock drop following analyst downgrades and concerns over clinical trial data for their drug, sonelokimab, with RBC Capital citing uncompetitive effect size. The community is debating whether the sell-off is an overreaction, with some seeing a buying opportunity due to the company's cash reserves and pipeline, while others express concern over biotech volatility and potential risks. Discussions also include speculation about potential buyouts and the impact of institutional ownership on the stock's price movement.

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

Dogwood Therapeutics Inc.

Dogwood Therapeutics is trending as traders discuss its low float and potential for a significant price surge, drawing comparisons to similar past runners. The community is closely watching for news related to upcoming Phase 2 data on Halneuron and potential partnerships for IMC-1, with some speculating on a potential squeeze due to limited shares available for borrowing.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as the crypto community focuses on its potential to represent and revolutionize cannabis culture. Discussions highlight Weedcoin's mission to foster a positive community and bridge culture with cryptocurrency. Some traders are speculating about potential catalysts from cannabis-related news and broader discussions around the future of the cannabis industry.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X is trending as the community rallies around the meme-based token on the Solana blockchain, emphasizing its longevity and status as a Jupiter Strict List token. Community members are playfully engaging with the 'What's UpDog?' joke, fostering a lighthearted atmosphere while encouraging others to 'load' the token. The focus remains on community-building and shared humor within the $UPDOG.X ecosystem.

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Larimar Therapeutics is trending due to a significant pre-market slump triggered by reports of a high anaphylaxis rate in a drug study, specifically seven patients experiencing anaphylaxis and withdrawing from a long-term study. The community is torn between concerns about the side effects and optimism about the drug's potential, with some viewing the drop as an overreaction and a buying opportunity, while others are exiting their positions. Despite the setback, some believe the FDA's continued involvement suggests the program is not stalled and that the data still signals great potential.

JFB Construction Holdings is a commercial and residential real estate construction and development company, which engages in delivering services to commercial and residential markets. It operates through the following segments: Commercial Construction, Residential Construction, and Real Estate Development. The Commercial Construction segment includes all activities related to the construction of commercial properties. The Residential Construction segment focuses on the construction of residential properties including single-family homes and multi-family units. The Real Estate Development segment refers to the acquisition, development, and sale of real estate properties. The company was founded by Joseph F. Basille III on April 9, 2024 and is headquartered in Lantana, FL.

JFB Construction Holdings - Ordinary Shares - Class A

JFB is trending due to a recently announced private placement of approximately $44 million, sparking significant after-hours trading activity. The community is actively discussing the stock's potential for a short squeeze, noting its small float and high short interest. Some traders are also pointing to potential dilution from warrants associated with the private placement.

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

GLD is trending as gold prices reach new all-time highs, fueled by expectations of Fed rate cuts and safe-haven demand amid geopolitical tensions. The community is discussing whether this rally has more room to run, with some pointing to a potential currency collapse while others worry about overbought conditions and an impending correction. Broader market context includes de-dollarization and strong central bank buying, influencing the conversation around gold's role as a store of value.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending following a Morgan Stanley downgrade, citing concerns about Alzheimer's trial risks, prescription trends, pricing pressures, and competition; however, the community is actively debating whether this downgrade is a strategic move to accumulate shares cheaply before positive news emerges, with some suggesting analysts are manipulating the stock for their benefit. While some express concern about the increased competition and potential margin squeeze, others emphasize the company's history of innovation and potential for long-term growth, particularly with its upcoming oral Wegovy and expansion into key markets like India.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USAR is trending due to news around potential government funding and strategic initiatives in the rare earth sector, including discussions of reallocating funds from the CHIPS Act. The community is actively discussing the implications of these developments, particularly in relation to domestic supply chains and competition with China. Some are also noting insider selling, as well as upcoming milestones for the company's magnet production and mine development.

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals (ENTA) is trending due to mixed Phase 2b study results for its RSV treatment, zelicapavir, causing investor debate and a stock sell-off. While the primary endpoint was missed, secondary endpoints were met, fueling discussions about the drug's potential and Phase 3 progression, particularly regarding FDA priorities. Community talking points include potential short squeezes given the high short interest and oversold RSI.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Progress Software Corp. (PRGS), an artificial intelligence-powered application development platform provider, are in the spotlight ahead of its quarterly results.The Burlington, Massachusetts-based company is scheduled to report its financial results for the third quarter of the fiscal year 2025 after the market closes on Monday. According to Fiscal.ai, the company is expected to report adjusted earnings per share (EPS) of $1.30, up from $1.26 reported for the same period in the previous year. Revenue is expected to rise more than 34% year-over-year to $240.11 million.The guidance issued in late June called for adjusted third-quarter EPS of $1.28-$1.34 and revenue of $237 million to $243 million. At that time, the company raised its full-year guidance to $5.28 to $5.40 and $962 million to $974 million, respectively.Among the key metrics the market would look forward to are the annual recurring revenue (ARR) and adjusted operating margin.On Stocktwits, retail sentiment toward&nbsp;<a href="https://stocktwits.com/symbol/PRGS">Progress Software stock</a> shifted to ‘bullish’ (73/100) as of early Monday, down from ‘extremely bullish’ the day before. The message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:616/54;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_29_at_4_37_47_AM_png_d38f6ad99c.webp" alt="Screenshot 2025-09-29 at 4.37.47 AM.png" width="616" height="54"><figcaption>PRGS sentiment and message volum as of 4:30 a.m. ET, Sept. 29 | source: Stocktwits</figcaption></figure>During the quarter, Progress Software announced AI-powered threat detection and incident response solutions for organizations, as well as a significant expansion of its AI-powered developer capabilities in its developer toolsets, Progress Telerik and Progress Kendo UI. It also unveiled Progress Federal Solutions, a wholly owned subsidiary established to serve the specialized needs of U.S. federal, defense, and public sector organizations.Progress Software stock has lost about 36% this year, underperforming the nearly 6% gain for the&nbsp;<a href="https://stocktwits.com/symbol/XSW">SPDR S&amp;P Software &amp; Services ETF (XSW)</a>. Analysts’ average price target for the stock is $83, according to Koyfin. This implies roughly 67% upside from the stock’s Friday close.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/retail-traders-evenly-split-about-government-shutdown-odds/chDMMmrR37S">Retail Traders Evenly Split About Government Shutdown Odds: Strategists Weigh In On Whether Jobs Report Would Be Delayed Amid Looming Risk</a>

2025/03/06: In this photo illustration, the Progress Software Corporation logo is seen displayed on a smartphone screen. 

Progress Software Analysts Project 67% Upside For Stock: Can Q3 Earnings Spark A Rally

According to Fiscal.ai, the company is expected to report adjusted earnings per share (EPS) of $1.30 and revenue of $240.11 million.

Equity

According to Fiscal.ai, the company is expected to report adjusted earnings per share (EPS) of $1.30 and revenue of $240.11 million.


What Analyst Projections for Key Metrics Reveal About Progress Software (PRGS) Q3 Earnings

Evaluate the expected performance of Progress Software (PRGS) for the quarter ended August 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Adobe Systems (ADBE) Q3 Earnings and Revenues Top Estimates

Adobe (ADBE) delivered earnings and revenue surprises of +2.71% and +1.50%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?

Synopsys (SNPS) Lags Q3 Earnings and Revenue Estimates

Synopsys (SNPS) delivered earnings and revenue surprises of -11.72% and -1.61%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?

Is the Options Market Predicting a Spike in Progress Software Stock?

Investors need to pay close attention to PRGS stock based on the movements in the options market lately.

Progress Software (PRGS) International Revenue Performance Explored

Explore how Progress Software's (PRGS) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

Company News for Jul 2, 2025

Companies In The News Are: PRGS, MSM, GEV, TSLA.

Tesla, AeroVironment and Progress Software fall premarket; MSC Industrial rises

Investing.com -- U.S. stock futures slipped lower Tuesday, dropping back from record levels as investors digested the latest news on trade deals, the Trump administration’s tax bill as well as upcoming key economic data.

Progress Software (PRGS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Progress Software (PRGS) give a sense of how the business performed in the quarter ended May 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Progress Software (PRGS) Q2 Earnings Beat Estimates

Progress Software (PRGS) delivered earnings and revenue surprises of +7.69% and -0.21%, respectively, for the quarter ended May 2025. Do the numbers hold clues to what lies ahead for the stock?

Progress Software Corp. engages in the provision of products that develop and deploy mission-critical business applications. Its products and solutions include Chef, Corticon, DataDirect, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity & WhatsUp Gold. The company was founded by Joseph Wright Alsop, Clyde Kessel, and Charles Arthur Ziering in 1981 and is headquartered in Burlington, MA.

Progress Software Corp.

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Current Price	$42.02
Prev Close	$41.20
Open	$41.17
Dividend Yield	0.77%
50-Day Moving Average	$44.98
Beta	0.71
Avg. Volume	799,681.90
PE Ratio	32.17

52-Week High	$70.56
52-Week Low	$40.29
Market Capitalization	$1.81B
EPS (Annual)	$1.54
Price to Book	4.00
Revenue Per Employee	$267,640.85
Enterprise Value/EBITDA	N/A

PRGS
Progress Software Corp.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PRGS News

PRGS Progress Software Corp.